Dynasty Wealth Management LLC Buys Shares of 14,341 Ionis Pharmaceuticals, Inc. $IONS

Dynasty Wealth Management LLC purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 14,341 shares of the company’s stock, valued at approximately $938,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Root Financial Partners LLC acquired a new position in Ionis Pharmaceuticals in the third quarter valued at approximately $88,000. Amalgamated Bank raised its position in shares of Ionis Pharmaceuticals by 5.8% during the 3rd quarter. Amalgamated Bank now owns 12,195 shares of the company’s stock valued at $798,000 after acquiring an additional 669 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Ionis Pharmaceuticals by 66.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 862,593 shares of the company’s stock valued at $56,431,000 after purchasing an additional 343,409 shares during the period. Nwam LLC acquired a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $232,000. Finally, Meeder Asset Management Inc. boosted its position in shares of Ionis Pharmaceuticals by 620.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock worth $47,000 after purchasing an additional 614 shares during the last quarter. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Stock Up 1.6%

NASDAQ:IONS opened at $77.53 on Wednesday. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.15. The firm has a market capitalization of $12.56 billion, a price-to-earnings ratio of -45.88 and a beta of 0.28. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The stock’s 50 day moving average price is $78.90 and its two-hundred day moving average price is $64.33.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.35. The company had revenue of $156.72 million during the quarter, compared to the consensus estimate of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.95) EPS. Equities research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Ionis Pharmaceuticals News Roundup

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Insider Buying and Selling

In other news, CEO Brett P. Monia sold 44,034 shares of the business’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $74.82, for a total transaction of $3,294,623.88. Following the transaction, the chief executive officer directly owned 224,683 shares in the company, valued at $16,810,782.06. The trade was a 16.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph H. Wender sold 28,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the completion of the sale, the director owned 36,035 shares of the company’s stock, valued at $2,912,348.70. This trade represents a 43.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 391,163 shares of company stock worth $30,183,387. Corporate insiders own 2.71% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on IONS. Wells Fargo & Company upped their price objective on Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, October 8th. The Goldman Sachs Group upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $45.00 to $65.00 in a report on Friday, September 26th. Leerink Partners increased their target price on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Finally, Stifel Nicolaus lifted their price target on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $87.05.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.